

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 July 2003 (24.07.2003)

PCT

(10) International Publication Number
WO 03/060524 A2

(51) International Patent Classification⁷: G01N 33/68

(21) International Application Number: PCT/CA02/02024

(22) International Filing Date:
30 December 2002 (30.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/343,859 28 December 2001 (28.12.2001) US

(71) Applicant (for all designated States except US): MDS
PROTEOMICS INC. [CA/CA]; 251 Attwell Drive,
Toronto, Ontario M9W 7H4 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DUEWEL, Henry
[CA/CA]; 350 Queens Quay West, Apt. 1310, Toronto,
Ontario M5V 3A7 (CA). GOH, Theo [CA/CA]; 1055 Bay
Street, Apt. 1116, Toronto, Ontario M5S 3A3 (CA). LEBI-
HAN, Thierry [CA/CA]; #206-3310 Fieldgate Dr., Missis-
sauga, Ontario L4X 2J1 (CA).

(74) Agent: BERESKIN & PARR; 40 King Street West, 40th
Floor, Toronto, Ontario M5H 3Y2 (CA).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

[Continued on next page]

(54) Title: ENZYME/CHEMICAL REACTOR BASED PROTEIN PROCESSING METHOD FOR PROTEOMICS ANALYSIS
BY MASS SPECTROMETRY



(57) Abstract: A method and tools for the biochemical processing of protein samples towards their analysis and identification by, for example, mass spectrometry (MS). The method involves the reversible (non-covalent) immobilization, purification and concentration of proteins onto a solid surface and subsequent solid-phase enzyme-catalyzed proteolysis of the proteins. The constituent peptides are recovered in near-quantitative yields in a format ideally suited for identification by routine MS technologies. The process is easily adapted such that additional chemical and/or enzymatic transformation(s) of the immobilized proteins or peptides can be performed to facilitate the acquisition of and increase the information content obtained from the MS analysis.

BEST AVAILABLE COPY



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**ENZYME/CHEMICAL REACTOR BASED PROTEIN PROCESSING METHOD FOR
PROTEOMICS ANALYSIS BY MASS SPECTROMETRY**

Reference to Related Applications

- 5 The present application claims priority to U.S. Provisional application 60/343,859, filed on December 28, 2001, the entire content of which is incorporated by reference herein.

Field of the Invention

- 10 The disclosed invention relates generally to the field of proteomics. More specifically the invention encompasses tools and procedures for enzymatic and/or chemical transformation of polypeptides. The transformed polypeptides serve as either analytes or products for a number of applications.

15 **Background to the Invention**

- Accurate and rapid sequence analysis of proteins and polypeptides has become crucial in the fields of biology, biotechnology and proteomics. Despite completion of the mapping of the human genome, a possible half million human proteins
20 encoded by some 30,000 genes must still be identified and characterized. The new discipline of proteomics aims to unravel biochemical information at the molecular level.

- At present, only a limited number of techniques have been developed to address the
25 growing need to quickly and accurately identify proteins through mass-accurate methods such as mass spectrometry. These current protein identification procedures and platforms involve the integration of three broad practices, including sample production or isolation, sample processing and sample analysis. The practices of sample production and analysis must be coupled by effective sample processing
30 methods for optimal implementation of a platform. Once the protein sample is isolated, sample processing routinely includes protein purification, preconditioning

(e.g. reduction and alkylation of cysteine residues) and concentration followed by degradation of the purified protein into constituent peptide fragments, either by chemical degradation or, more commonly, by enzymatic hydrolysis (e.g. by use of proteases). The peptides so produced are recovered and analyzed by mass spectrometry. This mass spectrometric data is then correlated with information contained in genomic and protein databases in order to identify the proteins in the original sample.

Conventional proteomic platforms rely heavily on either one- or two-dimensional gel electrophoresis for sample processing. Here, separation, purification and concentration of protein samples occur during electrophoresis. Following electrophoresis, separated proteins in the gel are visualized through differential staining and the protein-containing gel bands or spots of interest are excised. The protein-containing gel band or spot can then be treated to 'in-gel' chemical or enzymatic digestion, followed by extraction of the constituent peptides for later sequencing. Such gel-based processing method requires subjecting the gel band or spot to a series of drying and swelling procedures, in order to introduce the reagents for digestion and to extract the digested fragments. Alternatively, the protein can be transferred to a PVDF membrane for digestion or automated Edman degradation.

Significant problems exist with conventional gel-based processing platforms. Many proteins cannot enter the gel, or be separated in-gel, because of their physicochemical properties. In particular, hydrophobic proteins or proteins of high molecular mass are poorly processed by gel methods. Furthermore, detectability is limited to the sensitivity of the stain used for visualization. Proteins below this level, by definition, are precluded from subsequent analyses. Additionally, inherent limitations to the 'in-gel' chemical or enzymatic digestion of the proteins currently exist which lowers the overall sensitivity and performance of the method. These include the adverse effects of the gel matrix on the digest efficiency and the recovery of the constituent peptides.

Furthermore, gel-based processing platforms, by necessity, require numerous sample handling procedures and sample transfers. One implication of successive manipulations of the sample is loss of the protein prior to the digestion step, as well as loss of the constituent peptides prior to analyses. The losses at each step are
5 multiplicative, and compromise the overall sensitivity of the gel-based platform. Another implication of successive manipulations of the sample, especially when the methods are performed manually, is the increased potential of sample contamination, such as from dust or keratin (a protein in human skin and hair).

10 An attempt has been made to automate electrophoretic separations of macromolecules and, in particular, to automate two-dimensional electrophoretic separations used in the analysis of proteins (Anderson *et al.*, U.S. 6,245,206, 2001). Such two-dimensional procedures involve sequential separation of the proteins by isoelectric focusing (IEF) and sodium dodecylsulfate polyacrylamide gel
15 electrophoresis (SDS-PAGE), and a method involving the use of robotics and computer software to automate the manipulation of two-dimensional gel media. However, such a system is complex, capital intensive, inflexible and costly.

As an alternative to gel-based sample processing methods, other proteomic
20 platforms rely on solution-phase sample processing methods. Here, more conventional sample production approaches, such as sub-cellular fractionation, affinity chromatography, immunoprecipitation, and various other standard chromatography techniques (*e.g.* ion exchange, size-exclusion, or hydrophobic chromatography) are used to isolate the protein sample. Then, chemical or
25 enzymatic digestion of the proteins into their constituent fragments is performed in solution, either directly or following the addition of other reagents, as required, or following additional sample processing manipulations, as required.

The effectiveness of conventional solution-phase processing methods depends upon
30 a number of practical considerations. First, the chemical composition of the protein sample will be determined by the buffer components required for the solution-phase protein production method employed. Often, protein isolation requires the use of

high concentrations of salts, detergents or other additives that ultimately contaminate and dilute the sample. The presence of such contaminating additives can interfere with the efficient digestion of the protein into its constituent fragments during sample processing. The chemical and/or enzymatic transformation of proteins often
5 requires a specific set of solution conditions, such that the chemical environment of the protein sample (as determined through the application of conventional solution-phase sample processing) may result in the sample being unresponsive or incompatible to further chemical or enzymatic degradation. Furthermore, such contaminants may also interfere with the mass spectrometric analysis of the product
10 peptides, greatly reducing the quality of the data obtained.

Additionally, conventional solution-phase purification approaches result in the protein sample being obtained at dilute concentrations (*e.g.* sub micromolar range) in relatively large volumes (Figeys, D. and Pinto, D. Electrophoresis (2001) 22, 208-
15 216). This reduces the efficiency of the chemical or enzymatic digestion of the protein into its constituent fragments. For example, most commonly used proteases in proteomic platforms (*e.g.* trypsin) have K_m values in the low- to mid-millimolar range, and the digestion efficiency is significantly reduced as the concentration of protein is reduced below these levels. As such, the sample usually requires a pre-
20 concentration step in order for the digestion reaction to proceed in a kinetically favourable manner. Pre-concentration methods such as protein precipitation, solution evaporation or dry-down and ultrafiltration concentration introduce additional sample handling steps and, therefore, as in the case of gel-based processing, are sources of sample loss. The losses at each step are multiplicative
25 and compromise the overall sensitivity of the solution-phase processing platform. In addition, any preconcentration method will also result in the concentration of contaminants as well as the sample of interest; for reasons already discussed this is undesirable.

30 The field of proteomics generates very small quantities of sample indeed. For example, it may be desirable to analyze the proteome of a tissue from a single individual. In such cases it may only be possible to obtain milligram quantities of

whole tissues, which will contain only microgram quantities of total protein. Current sample processing methodologies are not capable of handling such limited quantities of protein efficiently.

- 5 Mass spectrometry (MS) provides a means of determining the mass of polypeptide digest fragments. Under the influence of electric and/or magnetic fields, the peptide-derived ions follow trajectories depending on their individual mass (m) and charge (z). Many applications of mass spectrometric methods are well known in the art (Meth. Enzymol., 193); (McCloskey, ed.; Academic Press, NY 1990; McLafferty
10 *et al.*, Acc. Chem. Res. 27:297-386 (1994); Chait and Kent, Science 257:1885-1894 (1992); Siuzdak, Proc. Natl. Acad. Sci., USA 91:11290-11297 (1994)). The spectrum of fragment masses can then be searched against a database to determine the sequence of the target protein (mass fingerprinting). In cases where mass fingerprinting cannot provide all the necessary data, "tag sequencing" (tandem
15 MS/MS peptide sequencing) can be used (Gross, Trends in Anal. Chem. 17 (1998) 470).

- A variety of mass spectrometry techniques are currently used in the sequencing of proteins, including Time of Flight (ToF), Q-trap, quadrupole-ToF (Qtof), ion-trap,
20 MALDI Time of Flight (MALDI-ToF); Fourier-Transform mass spectrometry (FT-MS) and tof-tof. Ionization techniques which may be employed include Matrix Assisted Laser Desorption/Ionization (MALDI) (Hillenkamp, Anal. Chem. 60 (1988) 2299); and Electrospray Ionization (ESI) mass spectrometry.

- 25 The use of mass spectrometry for identifying proteins has increased the importance of sample processing in order to provide a sample ideally suited for use in MS techniques. Sample processing methods for gel-based or solution-phase methods is a 'bottleneck' to the performance limits of detection (LOD) of the mass spectrometer. Current mass spectrometry technology is able to analyze peptides at
30 the attomolar level (10^{-18} mol); however, existing upstream sample handling processes, particularly in the case of gel-based or solution-phase methods, can at best process proteins obtainable in approximately femto- to lower pico-molar

amounts. This is due to the fact that losses are significant with the conventional gel-based and solution-phase sample processing methods.

5 Hsieh discloses a technique for automation of multidimensional separations through columns of differing selectivities (Hsieh, Anal. Chem. 1996). First, the target protein is purified by immunoaffinity chromatography. The protein is then digested in an immobilized trypsin column, after which the tryptic digest is transferred to a perfusion dilute capture column where it is concentrated and desalted. Peptides
10 eluted from the dilute capture column are analyzed by single-stage mass spectrometry (MS) or tandem MS/MS. Although this technique eliminates the amount of handling necessary for a particular sample, it requires relatively complicated multi-column chromatography.

Finally, Little et. al. (U.S. 6,322,970 B1, 2001) discloses a method of obtaining a
15 target polypeptide, immobilizing the target polypeptide to a solid support (preferably with a linker which is acid cleavable, acid-labile, heat sensitive or photo-cleavable), treating the immobilized target polypeptide with an enzyme or chemical to generate a series of deleted fragments, conditioning the cleaved fragments, cleaving the linker to release the immobilized fragments and determining the mass of the released
20 fragments. However, Little discloses the use of a covalent linker to the substrate, and does not teach pH-regulated immobilization of the polypeptides to an ionic substrate.

The above techniques suffer from a number of disadvantages. For example, in the
25 case of solution-based methods such as LC and HPLC disclosed above, the protein substrates are subjected to enzymatic and chemical transformations in solution or are transiently passed over a solid surface bearing immobilized enzymes or chemical reagents, thus reducing the efficiency of LC or HPLC relative to a situation in which proteins are surface immobilized.

30 An extended discipline of proteomics has recently emerged, termed quantitative proteomics. The discipline makes use of mass spectrometry and the proven

technique of stable isotope labeling [De Leenheer, A. P. and Thienpont, L. M. (1992) Mass Spectrom. Rev. 11, 249-307] as a means of protein quantification. The method involves the addition to the sample of a chemically identical form of the mass analyte (e.g. polypeptide fragment) that contains, or is labeled with, stable heavy isotopes (e.g. ^2H vs. ^1H , ^{13}C vs. ^{12}C , ^{18}O vs. ^{16}O). In its simplest form, polypeptides derived from one sample (e.g. State A) are combined with polypeptides derived from a second sample (e.g. State B). The polypeptides from State A are processed such that they are labeled with the "light" (i.e. unlabeled) version of an elemental isotope. By contrast, the polypeptides from State B are processed such that they are labeled with the "heavy" version of the same element. If both samples from State A and State B contain the same polypeptides, but at different relative amounts, then all polypeptides in the combined mixture will exist as analyte pairs of identical sequence and chemical composition, but will differ in mass by an amount equal to the difference between the light and heavy isotope. Thus, the ratio between the mass intensities of the light- and heavy-labeled polypeptide pair, as determined by routine mass spectrometry analysis, will provide a measure of the relative abundance of the polypeptide in the original samples, namely State A and State B.

Several applications of stable heavy isotope labeling for quantitative proteomics using mass spectrometry are known in the art. These include the practice of metabolic labeling of proteins *in vivo* during protein synthesis for example, with ^{14}N or ^{15}N [Conrads, T. P., Alving, K., Veenstra, T. D., Belov, M. E., Anderson, G. A., Anderson, D. J., Lipton, M. S., Pasa-Tolic, L., Udseth, H. R., Chrisler, W. B., Thrall, B. D., and Smith, R. D. (2001) Anal. Chem. 73, 2132-2139] or with labeled amino acids such as leucine- $^1\text{H}_{10}$ or leucine- $^2\text{H}_{10}$ [Martinovic, S., Veenstra, T. D., Anderson, G. A., Pasa-Tolic, L., and Smith, R. D. (2002) J. Mass Spectrom. 37, 99-107]. Other practices include the chemical labeling of proteins *in vitro*, which exploit the selective reactivity of an amino acid residue to derivatization with a light and heavy form of a chemical reagent or tag. For example, cysteine residues in proteins have been labeled using the light ($^1\text{H}_8$) and heavy ($^2\text{H}_8$) forms of the ICAT reagent [Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., and Aebersold, R. (1999) Nat. Biotechnol. 17, 994-999], or with the light ($^1\text{H}_3$) and

heavy ($^2\text{H}_3$) forms of acrylamide [Sechi, S. (2002) Rapid Commun. Mass Spectrom. 16, 1416-1424].

Another practice of stable isotope labeling involves the use of ^{18}O -labeled water (H_2^{18}O) in the course of the sample processing step of polypeptide digestion by proteases. All proteases commonly used in proteomic platforms (e.g. trypsin) catalyze hydrolysis of peptides bonds in which a water molecule from the bulk solvent reacts with a peptide carbonyl group, and the bond to the amino group of the next amino acid is cleaved [Kraut, J. (1977) Annu. Rev. Biochem. 46, 331-358]. By virtue of the catalytic mechanism, each proteolytic peptide generated (with exception of the C-terminal peptide of the protein) is expected to have at its carboxy terminus one oxygen atom originating from the original peptide carbonyl group and one oxygen atom incorporated from the bulk solvent. Thus, when ^{18}O -enriched water is present in the bulk solvent the extent of ^{18}O incorporation into each peptide will be a function of the relative $\text{H}_2^{18}\text{O}/\text{H}_2^{16}\text{O}$ ratio present in the digestion buffer.

The practice of ^{18}O -labeling is receiving increasing attention as a preferred method for heavy isotope labeling and several examples of its application have appeared [Stewart, I.I., Thomson, T. and Figeys, D. (2001) Rapid Commun. Mass Spectrom., 15, 2456-2465; Wang, Y.K., Ma, Z., Quinn, D.F. and Fu, E.W. (2001) Anal. Chem., 73, 3742-3750; Yao, X., Freas, A., Ramirez, J., Demirev, P.A. and Fenselau, C. (2001) Anal. Chem., 73, 2836-2842]. In general, the application of ^{18}O -labeling invokes the use of solution phase sample processing although reports using gel-based sample processing in conjunction with ^{18}O -labeling have also appeared [Kuster, B. and Mann, M. (1999) Anal. Chem. 71, 1431-1440; Kosaka, T., Takazawa, T. and Nakamura, T. (2000) Anal. Chem. 72, 1179-1185].

It is common practice and considered advantageous to use the highest enrichment of H_2^{18}O as possible in order to achieve the highest degree of labeling of each proteolytic fragment for quantitative proteomics applications. A severe limitation to the ^{18}O -labeling approach is the limited commercial availability and high cost of highly enriched (>95 atom % ^{18}O) H_2^{18}O [Ad Hoc Committee of the North

American Society for the Study of Obesity (1999) in 'Report on the Supply and Demand of ^{18}O Enriched Water', <http://www.naaso.org/newsflash/oxygen.htm>].

Current gel-based and solution-phase sample processing methods necessitate the use of relatively large volumes of H_2^{18}O . In addition, especially in the case of solution-phase sample processing, the sample, which will be isolated in a medium containing only natural abundance water (*i.e.* H_2^{16}O), must either be greatly diluted into H_2^{18}O containing buffers or the sample must be dried-down and then reconstituted in a small volume of H_2^{18}O -containing buffers in order to preserve a high enrichment percentage of H_2^{18}O in the final sample to be processed. Often, these methods are not feasible or compatible with optimal sample processing required for effective enzymatic degradation of the proteins. For example, dilution of the sample will lead to lowering the concentration of the protein sample. Dry-down pre-concentration will also result in concentration of contaminants in the sample. The negative effect of the latter sample processing steps on the enzymatic digestion has been addressed earlier.

There is currently no single technique, or combination of techniques, which fulfils the exacting needs of proteomic analysis. Such a technique must address a number of requirements related to protein sample handling and processing, including :

- a) reducing the number of sample transfers required, thus removing a significant source of sample loss,
- b) the capability of being carried out on-line in an integrated format, and that can be significantly automated,
- c) significantly increasing the amount of protein that is captured and analyzed to near quantitative yields, preferably without the need of gel-based separations,
- d) efficiently processing the very small quantities of material which a proteomics experiment generates, without the need for multiple experiments or sample pooling,

- e) consists of a single sample handling and loading step, and that does not require the transfer of protein samples onto and off of a gel or membrane, thus significantly reducing protein loss and dramatically reducing the labour required,
- 5 f) the capability that the sample volume of the final peptide solution should be significantly reduced, such that the entire sample is typically eluted in less than 10-20 μL of buffer,
- g) increasing the efficiency of proteolytic digestion of the proteins into peptide analytes and decreasing auto-digestion of the proteolytic enzyme,
- 10 h) the capability which allows for surface immobilization of sample proteins, thus increasing the effective concentration of the protein reactant 2-5 orders of magnitude compared to the equivalent solution phase reaction and allowing implementation of the chemical or enzymatic transformations that would otherwise not be possible in an industrialized platform *via* the
- 15 corresponding solution based methodology,
- i) allows for transfer of a protein sample isolated in relatively large volumes of natural abundance water (H_2^{16}O) into a medium containing highly enriched H_2^{18}O (> 95 atom % ^{18}O) without sample loss and allowing enzymatic digestion of the protein in said medium with concomitant high efficiency
- 20 labeling of the proteolytic fragments with ^{18}O at the carboxy terminus,
- j) the ability to achieve the capability as outlined in (i) while using only minimal amounts of H_2^{18}O (< 50 μL) per experiment, thus significantly reducing the cost associated with using highly enriched H_2^{18}O as a reagent, and
- 25 k) the capability as outlined in (i) and (j) that also encompasses requirements as outlined in (a-h).

Summary of the Invention

- 30 An invention, encompassing a number of tools, devices and procedures, has been developed which facilitates and improves upon current methods of polypeptide sample processing and current methods for the enzymatic and/or chemical

transformation of polypeptides. The transformed polypeptides are recovered in high yields, in a format ideally suited for routine mass spectrometry based analyses in applications directed towards protein identification and quantitation. The invention is easily adapted such that additional chemical and/or enzymatic transformation(s) of the immobilized polypeptides can be performed in order to facilitate the acquisition of, and increase the information content obtained from, the mass spectrometry analysis.

Disclosed is a method and apparatus for the processing of protein or peptide samples for their analysis and identification by known means, such as mass spectrometry (MS). The method involves the reversible (*i.e.* non-covalent) immobilization or capture and concentration of proteins onto a solid surface and subsequent solid-phase transformation (such as chemical modification and/or enzyme-catalyzed proteolysis) of the proteins. In a preferred embodiment, the constituent peptides are recovered in near-quantitative yields in a format ideally suited for identification by MS methodologies, including, but not limited to, various types of detection platforms (*e.g.* time-of-flight, ion trap, quadrupole and Fourier-transform) and ionization source-interfaces (*e.g.* MALDI, electrospray, nano-electrospray, and liquid-chromatography-MS). Moreover, any other analytical device useful for the detection or identification of proteins or peptides, currently used or hereinafter invented, can be used. The process is easily adapted such that additional chemical and/or enzymatic transformation(s) of the immobilized proteins or peptides can be performed.

Also disclosed is a method for the rapid and reliable sequencing and analysis of proteins, utilizing mass spectrometry to identify proteolytic fragments to determine polypeptide sequences. In one embodiment, the method includes the reversible immobilization or 'capture' of proteins or peptides onto a solid support. In a preferred embodiment, such reversible immobilization may be by pH- or ionic strength-dependent immobilization of proteins to a strong anionic surface, such as a cationic exchange resin. More generally, such reversible immobilization also contemplates use of cationic substrates, ion exchange resins, as well as mixed bed resins, hydrophobic resins and affinity columns.

The method includes a next step in which the reversibly immobilized proteins are subjected to solid phase-based chemical or enzymatic modification of the said proteins or peptides. For example, the proteins, while remaining immobilized on the surface, are digested with a proteolytic enzyme into their constituent peptides. In a particular embodiment, trypsin is used to digest the immobilized protein. In another example, cysteine residues are chemically reduced with dithiothreitol (DTT) and alkylated with iodoacetamide (IA).

The method also includes the further step in which peptide fragments produced from the proteolytic digestion are desorbed from the solid surface through a change in pH and/or cation or anion concentration and are recovered in an exceptionally small volume. The concentrated peptide solution requires no further purification and can be directly analyzed by MS techniques, including, but not limited to, various types of detection platforms (e.g. time-of-flight, ion trap, quadrupole and Fourier-transform) and ionization source-interfaces (e.g. MALDI, electrospray, nano-electrospray, and liquid-chromatography-MS). Moreover, any other analytical device useful for the detection or identification of proteins or peptides, currently used or hereinafter invented, can be used. The identity of the proteins can be obtained from database queries of MS derived data.

Also disclosed is a method that involves protein/peptide concentration and immobilization through ionic bonding of the proteins/peptides with the anionic surface through a cation exchange mechanism, and the subsequent chemical or enzymatic transformation of the immobilized protein/peptide in a highly efficient manner. In one particular embodiment, immobilization of the proteins/peptides is achieved when the proteins/peptides are applied to the surface using a low ionic strength ($\mu \leq 100\text{mM}$) buffer at pH 1-3. Under these conditions, all natural proteins/peptides will bear at least one cationic group and the net charge of the protein/peptide is greater than zero. For these reasons, the cationic protein/peptide moiety will exchange with a cationic counter-ion on the solid-surface and the protein/peptide becomes ionically bound to the surface immobilizing the protein/peptide to the surface. One advantage of this method is that the total amount of protein/peptide that can be immobilized onto the surface is dependent only upon

the binding capacity and amount of solid-surface employed, and not on the initial concentration of the protein/peptide in the binding buffer. Therefore, proteins/peptides present in small to large volumes can be concentrated and immobilized onto a given amount of solid-surface.

5 Another advantage of the method is the increased efficiency of proteolytic digestion of the proteins into peptide analytes. Protein samples are denatured during the immobilization process and exist in extended conformations on the surface. This presents the proteolytic enzyme with a dramatically improved digestion target, resulting in improved peptide production. For example, digestion of the
10 immobilized peptide or protein may give rise to fragments not found by solution digestion (due to limitations inherent in the kinetics of solution chemistry). Such information provides valuable sequencing information.

Another advantage is that the auto-digestion of the proteolytic enzyme, which can complicate MS analysis, is dramatically reduced. The described experimental
15 protocol results in the observance of practically no peptide fragments from the endoprotease itself. Auto-digestion of the protease is a common problem in gel-based and solution-phase processing methods and reduces the quality of the MS analysis.

Yet another advantage is that surface immobilization of the proteins/peptides can,
20 under practical conditions, increase the effective concentration of the protein/peptide reactants 2-5 orders of magnitude compared to the equivalent solution-phase reaction, thus allowing implementation of chemical or enzymatic transformations that would otherwise not be possible in an industrial platform which utilized solution- or gel-based methodologies.

25

A further advantage is that the disclosed method eliminates the performance 'bottleneck' that results from gel- or solution-based methods. Current mass spectrometry technology is able to analyze peptides at the attomole level (10^{-18} mol); however, existing upstream sample handling processes, particularly in the case of

gel-based or solution phase methods, can at best process proteins obtainable in approximately femto- to lower pico-molar amounts.

- 5 In particular embodiments of the method, protein immobilization is followed by one or more wash steps. The wash steps are selected to preserve the ionic bonding (immobilization) of the proteins/peptides to the surface. They also allow for the removal of contaminating species, necessary for efficient enzymatic or chemical transformation of the immobilized proteins/peptides. Such contaminating species may also compromise subsequent MS performance.
- 10 The immobilized proteins/peptides can be subjected to essentially an unlimited number of transformations based on chemical and enzymatic reactions. In a preferred embodiment, the immobilized protein/peptides are digested with trypsin in an ammonium bicarbonate buffer (to maintain trypsin activity). Other chemical and enzymatic agents may be used to transform the reversibly immobilized proteins,
- 15 including other endoproteases (*e.g.* chymotrypsin), exoproteases, kinases, methylases, glycosidases and phosphatases.

- Also disclosed is a device that allows for the streamlined sample handling and processing method as disclosed herein, integrating protein immobilization and concentration, enzymatic or chemical transformation of the immobilized protein, and
- 20 wash steps in a single column. In a particular embodiment the disclosed apparatus is a device that allows for on-line integration with standard MS devices, including MALDI, MALDI-Tof, Fourier transform MS, quadrupole MS, and ESI MS, or other techniques currently in use or hereinafter invented. In another embodiment, the disclosed device is a disposable high-throughput device.
- 25 In another embodiment, the disclosed device allows for sample volume of the final peptide solution to be significantly reduced, such that the entire sample is eluted in approximately 10-20 μL of buffer, dramatically increasing the concentration of the final peptide analytes and decreasing the need for further concentration. This greatly simplifies sample introduction to a mass spectrometer, for example.

Also disclosed is a device constructed from a fused silica column which houses a solid support (for example, a resin), a flow inlet and a flow outlet, wherein said solid support allows for reversible immobilization of a peptide or protein sample, enzymatic or chemical transformation of the sample into peptide fragments (or modified peptide fragments) while reversibly immobilized, and desorption of the peptide fragments from the solid support for collection and identification using any number of techniques, including mass spectrometry and Edman degradation, or other techniques currently known or hereafter invented.

Also disclosed is a device constructed from a capillary column that includes a strong cation exchange resin, a flow inlet and a flow outlet, such that the strong cation exchange resin in the column allows for reversible immobilization of a protein sample loaded into the column, along with a low pH buffer to lower the pH of the protein sample. The device allows for proteolytic digestion of the protein sample into peptide fragments while the fragments are reversibly immobilized, and desorption of the resulting peptide fragments from the solid substrate for collection and identification using mass spectrometry techniques. In particular embodiments, the device may be attached directly to a mass spectrometer for online collection and analysis of the protein fragments using standard mass spectrometry techniques.

Also disclosed is a method of constructing a device for the processing of peptide samples for analysis and identification by mass spectrometry, such that a column tube is packed with a solid substrate that allows for reversible immobilization of the protein. In a preferred embodiment, the solid substrate is a strong cation exchange resin. The column tube includes a flow inlet, and a flow outlet, such that when the protein sample is loaded into the column, the protein sample binds reversibly to the solid substrate. In particular embodiments, the protein sample is loaded into the device with a low-pH buffer, preferably in the range of pH 1-3. The device is constructed such that after proteolytic digestion of the peptide sample into peptide fragments while reversibly immobilized, the immobilized peptide fragments can be alternately washed using mobile wash steps, and subsequently desorbed and eluted from the solid substrate after treatment with a high pH buffer or high salt concentration. In particular embodiments, the device can be attached directly to a

mass spectrometer for online collection and analysis of the protein fragments using standard mass spectrometry techniques.

Reference to the Drawings

5 Figure 1. Fabrication and components of a device incorporating the enzyme/chemical reactor using columns prepared with commercially available fused silica tubing fittings.

10 Figure 2. Fabrication and components of a device incorporating the enzyme/chemical reactor using columns prepared with embedded strong cation exchange (SCX) resin/sol-gel frits.

Figure 3. Schematic of the pressure vessel solvent delivery system for the method of the present disclosure.

15 Figure 4. Schematic of the different modes of operation of the pressure vessel solvent delivery system showing operation of a 2-unit system.

20 Figure 5. A schematic showing a 6-unit solvent delivery system, each unit of which may be operated independently.

25 Figure 6. A silver-stained SDS-PAGE gel indicating that all proteins in the sample loaded onto the reactor became immobilized, and remained immobilized during subsequent wash steps. Lane (1) starting material (10 pmol/protein); (2) solution collected during the sample load step; (3) First wash fraction; and (4) Second wash fraction.

30 Figure 7. Mass spectrum (MS) and tandem mass spectrum (MS/MS) for (1) Phosphorylase B peptide TNFDAFPDK; (2) Phosphorylase B peptide HLQIIYEINQR;

Figure 8. Mass spectrum (MS) and tandem mass spectrum (MS/MS) for (1) BSA peptide LVNELTEFAK; (2) Carbonic anhydrase peptide VLDALDSIK.

Figure 9. Coomassie-stained SDS-PAGE gel of human SKB1 bait protein and its interacting proteins as eluted from the antibody resin using 50 mM phosphoric acid as a method to characterize the immunopurified complex. Another portion of the eluent was subjected to trypsin digestion using the protocols described under Section C (Basic Protocol) and mass spectrometry. Shown in the Table are the proteins identified from the database search of the mass spectrometry-derived data.

Figure 10. MALDI-TOF mass spectrum of the mixture of peptides 1, 2 and 3 after reduction and alkylation with iodoacetamide, following the instructions described under Section C (Alternate B Protocol). The graph indicates the relative proportions of the disulfide bonded, singly- and doubly-alkylated forms of peptides with 1, 2 and 3. Note that peptide 3 contains only 1 cysteine residue and thus, can only be singly-alkylated.

Figure 11. MALDI-TOF mass spectra of peptide mass fingerprints from the control sample, which was processed by only enzymatic digestion, and the experimental sample, which was processed by chemical reduction, alkylation with iodoacetamide and enzymatic digestion with trypsin. (A) Bovine Serum Albumin peptides RPCFSALTPDETYVPK from the control sample and RPCFSALTPDETYVPK + 1 iodoacetamide from the experimental sample; (B) Bovine Serum Albumin peptides LKPDNTLCDEFKADEK from the control sample and LKPDNTLCDEFKADEK + 1 iodoacetamide from the experimental sample; (C) Bovine Serum Albumin peptides SLHTLFGDELCK from the control sample and SLHTLFGDELCK + 1 iodoacetamide from the experimental sample.

Detailed Description of the Invention

Definitions

For convenience, certain terms employed in the specification, examples, and appended claims are collected here.

"Binding," "bind" or "bound", used interchangeably with "immobilizing", "immobilize" or "immobilized", refers to an association, which may be a stable association between two molecules, *e.g.*, between a modified protein ligand and an affinity capture reagent, due to, for example, electrostatic, hydrophobic, ionic and/or hydrogen-bond interactions under physiological conditions.

"Cells," "host cells" or "recombinant host cells" are terms used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

The term "Interacting Protein" is meant to include polypeptides that interact either directly or indirectly with a protein of interest (the "bait" protein). Direct interaction means that the proteins may be isolated by virtue of their ability to bind to each other (*e.g.* by coimmunoprecipitation or other means). Indirect interaction refers to proteins which require another molecule in order to bind to each other. Alternatively, indirect interaction may refer to proteins which never directly bind to one another, but interact *via* an intermediary.

The term "isolated", as used herein with reference to the subject proteins and protein complexes, refers to a preparation of protein or protein complex that is essentially free from contaminating proteins that normally would be present in association with the protein or complex, *e.g.*, in the cellular milieu in which the protein or complex is found endogenously. Thus, an isolated protein complex is isolated from cellular components that normally would "contaminate" or interfere with the study of the complex in isolation, for instance while screening for modulators thereof. It is to be understood, however, that such an "isolated" complex may incorporate other proteins the modulation of which, by the subject protein or protein complex, is being investigated.

"Analyzing a protein by mass spectrometry" or similar wording refers to using mass spectrometry to generate information which may be used to identify or aid in identifying a protein. Such information includes, for example, the mass or

molecular weight of a protein, the amino acid sequence of a protein or protein fragment, a peptide map of a protein, and the purity or quantity of a protein.

The term "purified protein" refers to a preparation of a protein or proteins which are preferably isolated from, or otherwise substantially free of, other proteins normally associated with the protein(s) in a cell or cell lysate. The term "substantially free of other cellular proteins" (also referred to herein as "substantially free of other contaminating proteins") is defined as encompassing individual preparations of each of the component proteins comprising less than 20% (by dry weight) contaminating protein, and preferably comprises less than 5% contaminating protein. Functional forms of each of the component proteins can be prepared as purified preparations by using a cloned gene as described in the attached examples. By "purified", it is meant, when referring to component protein preparations used to generate a reconstituted protein mixture, that the indicated molecule is present in the substantial absence of other biological macromolecules, such as other proteins (particularly other proteins which may substantially mask, diminish, confuse or alter the characteristics of the component proteins either as purified preparations or in their function in the subject reconstituted mixture). The term "purified" as used herein preferably means at least 80% by dry weight, more preferably in the range of 95-99% by weight, and most preferably at least 99.8% by weight, of biological macromolecules of the same type present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 5000, can be present). The term "pure" as used herein preferably has the same numerical limits as "purified" immediately above. "Isolated" and "purified" do not encompass either protein in its native state (*e.g.* as a part of a cell), or as part of a cell lysate, or that have been separated into components (*e.g.*, in an acrylamide gel) but not obtained either as pure (*e.g.* lacking contaminating proteins) substances or solutions. The term isolated as used herein also refers to a component protein that is substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.

"Sample" as used herein generally refers to a type of source or a state of a source, for example, a given cell type or tissue. The state of a source may be modified by certain treatments, such as by contacting the source with a chemical

compound, before the source is used in the methods of the invention. It should be noted that protein interaction network data based on "a sample" does not necessarily comprise results obtained from a single experiment. Rather, to completely determine a protein interaction network, multiple experiments are often needed, and the combined results of which are used to construct the protein interaction network data for that particular sample.

"Solid support" or "immobilization surface," used interchangeably, refers to a material which is an insoluble matrix, and may (optionally) have a rigid or semi-rigid surface, and which has the capability to bind proteins or peptides. Such materials may take the form of small beads, pellets, disks, chips, dishes, multi-well plates, wafers or the like, although other forms may be used. In some embodiments, at least one surface of the substrate will be substantially flat.

"Transforming", as used in "transforming protein" or the like, means change the original form of an intact protein (or fragment thereof) by one or more of: enzymatic or chemical digestion, modification (either on side chain or amino acid backbone, such as alkylation, etc.), reduction, oxidation, isotope labeling, covalently linking to a moiety, etc., or combination thereof (also called "serial transformation").

The terms "reactor", "device" and "apparatus" are somewhat interchangeable, and refer to various aspects of the invention disclosed herein. The reactor is the basic unit, comprising the solid support. The device comprises the combination of the reactor and components which allow it to be connected, for example, to a solvent delivery system. The apparatus is the combination of the device and a solvent delivery system. Optionally, the apparatus is further connected to an analytical device such as a mass spectrometer.

Overview

Disclosed is a method and device for allowing the purification, concentration and reversible immobilization of a protein in a nascent state onto a solid support, with the removal of any residual solvent and solute contaminants. The solid support may be a resin such as an ion-exchange resin, a hydrophobic support or an affinity support, for example. Ion exchange resins, including cationic, anionic and mixed

bed resins may be used. In a preferred embodiment a cation exchange resin is employed. The immobilization surface may be fabricated in the form of a column (such as a fused-silica column whose internal wall forms the immobilization surface), a surface such as a glass chip or well, or a resin-packed pipette tip, for example. After immobilization and concentration of the protein, weakly cationic, neutral and anionic contaminating species are removed from the surface using appropriate mobile phase wash steps. The mobile phase wash steps are selected to preserve the immobilization of the proteins to the surface. The mobile phase wash steps also allow for the removal of contaminating species, necessary for subsequent enzymatic or chemical transformation of the immobilized proteins and to aid in resolution for sensitive MS detection of peptide fragments.

Following the above steps the immobilized protein is subjected to one or more enzymatic or chemical treatments. In a preferred embodiment, all solvent is removed from the immobilization surface prior to such treatment. This may be accomplished, for example, with pressurized gas (e.g. nitrogen or argon; which, opportunistically, provide an inert atmosphere) essentially dehydrating the surface of all solution. A key advantage of such a dehydration step is that the solution containing the enzymatic/chemical reagents can itself be used to rehydrate (or saturate) the immobilization surface, filling only the interstitial volume thereof (i.e. in a column format this is equivalent to adding only enough solution to fill the column void volume). For this reason, very small volumes of solution (~ 50 nL) and amounts of reagents (~ pmol) are required. By such treatment, proteins remain either ionically bonded to the surface (in flow-through mode) or enter the mobile phase but remain within the surface bed but are not lost. This leads to a dramatic increase in the effective concentration of the reacting protein substrate and enzyme or chemical reactants.

Note that the dehydration/rehydration steps need not follow one another immediately. That is, after dehydration the immobilized proteins/peptides may be stored (under appropriate conditions) and processed at some later time. This advantage has obvious implications in automation, for example; a number of

samples can be immobilized, dehydrated, and then transformed at a later stage of an automated process.

As described herein, two column formats for the reactor device are used. In one embodiment, columns are prepared using commercially available fused silica tubing fittings. The filter end fitting (4; Figure 1) forms a physical plug or frit at the base of the column to constrain the SCX resin within the column. By necessity, this type of fitting requires the use and assembly of additional components to the column (2-4, 6, 17-19; Figure 1) in order to form the flow outlet (21; Figure 1).

In the second embodiment, the reactor device is assembled using columns prepared with embedded SCX resin/sol-gel frits using a proprietary method. In this format, the physical plug or frit at the base of the column is physically integrated into the column, and thus, the column and the flow outlet of the column is formed from a single integrated component (7, 8, 21; Figure 2). In this format, all the additional fittings required to form the column and the flow outlet (2-4, 6, 17-19; Figure 1) for columns prepared using commercial fittings are not needed, which reduces the time required to assemble the device.

The first column format is described as an 'easy to make' alternative to those users who are not skilled in the art of sol-gel chemistry and the preparation of sol-gel embedded frits, since the components to fabricate the first format of the device are commercially available and no special skills are required. The second format of the column is described for users that have the capacity to become skilled in the art of sol-gel chemistry and the preparation of sol-gel embedded frits. The second format has some advantages over the first; these include the ability to prepare columns in large numbers in both a cost- and labour-effective manner. Additionally, one of the steps performed in routine operation of the reactor device, namely the rehydration step is performed more straightforwardly with columns prepared with embedded frits.

A preferred embodiment of the invention uses a device that requires a solvent delivery system capable of operating in the micro-flow realm for optimal operation. More specifically, a solvent delivery system is needed that can efficiently generate solvent flow rates at approximately 5 $\mu\text{L}/\text{min}$ and, furthermore, generate said flow rates at a low operating pressure (<150 psi). Several micro-flow capillary HPLC instruments are commercially available that are capable of micro-flow solvent delivery. However, these instruments are extremely capital intensive. Furthermore, commercial instruments have basal operating pressures that typically exceed 500 psi and require relatively large volumes of solvents to completely purge and fill the internal fluid components (*e.g.* pumps, connective tubing).

In a preferred embodiment of the invention, the solvent delivery system must also be able to promote the complete transfer of a small volume of solvent (in cases, $< 5 \mu\text{L}$) from a solvent vial to and then subsequently through the device. In addition, the solvent delivery system must also be able to operate in a stop-flow mode and further, be able to purge the device of all solvent preferably using an inert gas source. At present, commercial micro-flow HPLC instruments are incapable of meeting these requirements.

The solvent delivery system designed in-house is described herein. As illustrated in Figure 3, a pressure vessel unit is constructed from two separate blocs of material (*e.g.* stainless steel or polymer). The upper bloc (8a) and the lower bloc (8b) are separable, and can be maintained together by constraining with screws, clamps or other mechanisms, thus forming a single unit. The O-ring (10) ensures that the unit is gas-tight. The lower bloc contains a cavity (or multiple cavities) of specific dimensions adapted for placement of a vial or tube. The upper bloc contains a cavity of similar dimensions, and is connected to a pressurized gas source *via* inlet connector (9a). One end of a fused silica tubing (3; usually 50 μm inner diameter by 360 μm outer diameter and 10-15 cm in length) is inserted exactly to the bottom of the vial (4b). The other end of the fused silica tubing is passed through a connector (9b), which holds it in place and forms a gas-tight seal. This end of the tubing forms the flow outlet of the pressure vessel solvent delivery system. This end of the tubing

is inserted into a 1.5 cm length of capillary sleeve such that the ends of the tubing and the sleeve are flush. The sleeve-covered tubing is inserted into a fingertight fitting (15; Figures 1, 2) such that the end of the flush sleeve-covered tubing protrudes through the fingertight fitting by approximately 1 mm. The fingertight fitting is then screwed into the opening (14; Figures 1, 2) of the ZDV (zero dead volume) union (13; Figures 1, 2) of the flow inlet to the reactor.

In operation, a vial is filled with a desired volume of solvent and placed into the cavity of the lower bloc. The upper bloc and affixed tubing is aligned and brought together with the lower bloc and the blocs constrained together. The pressurized gas source is then opened. At sufficient pressure, the solvent in the vial is forced through the fused silica tubing towards the flow outlet of the pressure vessel. As the flow outlet of the pressure vessel is connected with the flow inlet of the device (2, Figure 3), the solvent continues to flow through the reactor column, through the packed SCX resin and, finally, the solvent exits through the flow outlet of the reactor column into receptacle 4a. The operating pressure of the pressurized gas source controls the solvent flow rate.

An operating pressure of approximately 100 psi results in a flow rate of approximately 5 $\mu\text{L}/\text{min}$ with reactors fabricated with columns made with 200 μm inner diameter by 360 μm outer diameter fused silica tubing. An operating pressure of approximately 50 psi produces a flow rate of approximately 5 $\mu\text{L}/\text{min}$ with reactors fabricated with columns made with 320 μm inner diameter by 425 μm outer diameter fused silica tubing.

The unit may be operated in semi-automatic mode by employing automatic actuated valves (6a and 6b, and 7), and feedback (*i.e.* automatic purging) can be ensured either by a micro-flow sensor after reactor (2), or by a micro switch.

Multiple units may be combined, preferably in a suitable framework structure or manifold, to permit the simultaneous operation of multiple reactor devices. Figure 4

illustrates the different modes of operation of such a device. For clarity, only 2 units are shown, but the number of units which may be so employed is not limited.

The 2 different valve positions are:

- For valve 1: pressurized line OR purge line
- 5 - For valve 2: connected gas line unit OR purge unit

In mode 1, valve 1 is in pressurized line mode AND valves 2 are in connected gas line unit mode, allowing the entire unit to be pressurized at the same time.

- 10 In mode 2, Valve 1 is in purge mode AND valves 2 are in connected gas line unit mode, thus allowing purging of the entire unit at the same time (by just using valve 1).

- 15 In mode 3, Valve 1 is in pressurized line mode, valve 2a is in connected gas line unit mode AND valve 2b is in purge unit mode. Thus, the pressure is maintained in unit 1 (liquid flow) and not in unit 2 (stop liquid flow).

- 20 In a further refinement, illustrated in Figure 5, each unit of a multi-unit device may be operated independently of all other units. Pressure independence between units is ensured by O-ring (1).

- 25 As described herein, two column formats for the reactor device are used. In one embodiment, columns are prepared using commercially available fused silica tubing fittings. The filter end fitting (4; Figure 1) forms a physical plug or frit at the base of the column to constrain the SCX resin within the column. By necessity, this type of fitting requires the use and assembly of additional components to the column (2-4, 6, 17-19; Figure 1) in order to form the flow outlet (21; Figure 1).

Materials

The solid phase surface can be presented in the form of a cation exchange resin (beads) or as a cationic functionality bonded to the surface of chip (e.g. metal, glass) or polymeric membrane. The solid surface can be used in a batch format or can be housed in several formats including packed column and pipette tip. A preferred embodiment uses a strong cation exchange resin housed in a capillary illustrated in Figures 1 and 2 and described in section A, below. Protein samples can be present in aqueous or aqueous miscible organic solvents and the overall process can be performed manually or through automation. The protein/peptide can be either purified preparations or more complex samples derived directly from biological systems/organisms. Use of standard proteins and immunopurified protein complexes isolated from human cells is demonstrated at Examples 1 and 2, respectively.

Enzymatic and Chemical Transformations

In principle, the immobilized protein/peptide can be subjected to an unlimited number of transformations based on chemical and enzymatic reactions. For enzymatic reactions, a reaction solution containing the enzyme and any required co-factors is applied to the solid surface containing the immobilized protein/peptide, either in a flow-through manner or by allowing the enzyme solution to rehydrate the solid support. The enzyme solution is prepared and applied to the immobilized protein substrate using the optimal buffer conditions for the desired enzymatic reaction. The solid-phase enzymatic reaction is permitted to proceed for a certain time, after which the protein/peptide enzymatic products are displaced from the surface using 2-5 bed volumes of eluting buffer (for example, when using a cation exchange resin, a buffer having a high cation concentration and/or pH > ~8 is employed). The stringency of the eluting buffer can be adjusted to offer selective eluting capabilities.

The basic scope of the method can be extended to chemical reactions by simply applying a solution containing the desired chemical(s) to the immobilized

protein/peptide surface. Exemplary procedures used for enzymatic reactions can be similarly applied to chemical transformations.

Nature of Enzymatic and Chemical Transformations

The method is applicable to a wide range of enzymatic reactions, and is restricted only by the availability of the desired enzyme and required cofactors. Although any enzymatic reaction involving the immobilized protein/peptide substrate can be performed using the described method, preferred embodiments focus primarily on the application of endoproteases (*e.g.* trypsin, chymotrypsin), kinases, glycosidases and phosphatases. Experimental results have been gathered for the proteolytic enzyme trypsin, as set forth in Examples 1, 2, 4 and 5. For a particular application in the case of endoprotease reactions, the reaction solution is prepared using heavy water (^{18}O), resulting in the incorporation of the ^{18}O label into the proteolytic peptides, as set forth in Example 5.

In the case of chemical reactions relevant to the invention, any type of solution phase protein chemistry (aqueous, organic or combination) can be used in the process including, but not limited to :

1. DTT and TCEP reduction of disulfides
2. sulfhydryl alkylation with any *N*-alkylated iodoacetamide derivative (*e.g.* iodoacetamide, ICAT, PEO Iodoacetyl Biotin)
3. carbodiimide-mediated activation or crosslinking
4. esterification of carboxylic acid groups
5. DANSYL chloride modification of the side chain of Lysine residues and N-terminal amino groups.

Serial Transformations

The method can be extended to allow several reactions to be performed on the same immobilized protein/peptide sample. Under carefully controlled wash conditions the

first reaction solution (either chemical or enzymatic) can be removed from the surface while maintaining the immobilization of the protein/peptide to the surface. The resin can be washed and dehydrated as described previously. Then a second reaction solution (either chemical or enzymatic) can be applied to the surface-immobilized protein/peptide. The process can be repeated permitting several serial chemical or enzymatic reactions to be performed on the protein/peptide. An example of this principle has been achieved for serial reactions involving DTT reduction, sulfhydryl alkylation with iodoacetamide and digestion with trypsin (Example 4).

10 **Mass Spectrometry Detection**

The invention is applicable to several types of mass spectrometry detection platforms (e.g. time-of-flight, ion trap, quadrupole, and Fourier-transform) and ionization source-interfaces (e.g. MALDI, electrospray, nano-electrospray, and liquid-chromatography-MS). Although the method described is based on the use of mass spectrometry for protein analysis and identification, any other analytical device useful for the detection or identification of proteins/peptides can be used, either currently used or hereinafter invented. This could include fluorescence detection methods, UV spectroscopy, and radioactive isotope labeling.

20 **A. Reactor Fabrication and Components (Refer to Figure 1)**

The production of a preferred device includes fabrication of the individual hardware components and processes to integrate these into the final working apparatus, as detailed below for a column reactor. These include a pre-conditioned SCX resin substrate; a fused silica column which houses the SCX resin (two formats are described); a process to pack the column with the pre-conditioned SCX resin; a flow inlet and flow outlet permitting solvent delivery into and out of the column packed with SCX resin; and a pressure vessel solvent delivery system.

Materials Used. PolySULFOETHYL Aspartamide strong cation exchange resin (12 μm particle size; 300 angstrom pore size), hereafter referred to as SCX resin, is a product from The Nest Group, Inc. (Southborough, MA). Fused silica capillary tubing (200 μm inner diameter by 360 μm outer diameter; 320 μm inner diameter by 5 425 μm outer diameter) is a product of Polymicro Technologies (Phoenix, AZ). Fused silica capillary tubing fingertight fittings (product F-125), sleeves (products F-185X and F-186X for use with 360 μm outer diameter and 425 μm outer diameter tubing, respectively), ZDV unions (product P-720), and inline microfilters composed of a filter end fitting and microfilter union (product M-520) are products of 10 Upchurch Scientific (Oak Harbor, WA).

1) SCX Resin Pre-Conditioning.

One-gram of SCX resin was transferred to a 50 mL centrifuge tube. Methanol (40 mL) was added and the slurry was vortexed vigorously for 10 min. The resin was 15 pelleted by centrifugation ($1000 \times g$) and the supernatant decanted. A 1:1 solution of methanol:water (40 mL) was added and the slurry was vortexed vigorously for 10 min. The resin was again pelleted by centrifugation ($1000 \times g$) and the supernatant decanted. Water (40 mL) was added and the slurry was vortexed vigorously for 10 min. The resin was pelleted by centrifugation ($1000 \times g$) once more and the 20 supernatant decanted. A solution of 0.2 M sodium phosphate (monobasic) and 0.3 M sodium acetate (40 mL) was added and the slurry was subjected to continuous mixing by rotation of the centrifuge tube for 24 hr. The resin was collected by centrifugation ($1000 \times g$) and the supernatant decanted. A solution of 2 M potassium chloride, 10 mM potassium phosphate (pH 3; 40 mL) was added and the 25 slurry was subjected to continuous mixing by rotation of the centrifuge tube for 4 hr. The resin was collected by centrifugation ($1000 \times g$) and the supernatant decanted. A solution of 10 mM potassium phosphate (pH 3; 40 mL) was added and the slurry was subjected to continuous mixing by rotation of the centrifuge tube for 24 hr. The resin was collected by centrifugation ($1000 \times g$) and the supernatant decanted. 30 Water (40 mL) was added and the slurry was subjected to continuous mixing by rotation of the centrifuge tube for 3 hr. The resin was collected by centrifugation ($1000 \times g$) and the supernatant decanted. This latter process of washing the resin

with water was repeated two more times. The final pre-conditioned resin pellet was stored at 4°C prior to use.

2. Column fabrication.

5 2.1. Columns prepared using commercially available fused silica tubing fittings (Refer to Figure 1).

The method described was the same whether using either 200 µm inner diameter by 360 µm outer diameter or 320 µm inner diameter by 425 µm outer diameter fused silica capillary tubing. A 5 cm length of fused silica (1) was cut using a fused silica
10 cutter. One end of the cut tubing was placed into a 1.5 cm length of capillary sleeve (2), such that the ends of the tubing and the sleeve were flush. The sleeve-covered end of the tubing was inserted into a fingertight fitting (3) such that the flush sleeve-covered end of the tubing protrudes through the fingertight fitting by approximately 1 mm. The fingertight fitting was then screwed into a filter end fitting (4), which
15 was subsequently screwed into the filter end fitting opening (5) of a microfilter union (6). This furnished the completed column, which was then packed with SCX resin as described below (Section 3).

20 2.2. Columns prepared with embedded SCX resin/sol-gel frits (Refer to Figure 2).

The method described was the same whether using either 200 µm inner diameter by 360 µm outer diameter or 320 µm inner diameter by 425 µm outer diameter fused silica capillary tubing. A sufficient amount of fused silica tubing (e.g. 1-2 m) was rinsed with methylene chloride (approximately 2 mL/m of tubing) and then purged
25 and dried with a stream of nitrogen gas at 40 psi for 1 hr. The amount of tubing ultimately treated in this manner was determined by the desired number of columns to be fabricated. The initial length of dried tubing was then cut into 5 cm lengths using a fused silica cutter.

30 A previously reported method based on sol-gel chemistry (Zhang, X. and Huang, S. (2001) J. Chromatogr. A 910, 13-18) was modified extensively to produce columns with embedded frits. In the preferred method, a sol-gel solution was prepared by the

sequential addition of trifluoroacetic acid (100 μ L), methyltriethoxysilane (75 μ L), water (10 μ L) and methanol (200 μ L) to a glass vial. The vial was sealed and the solution sonicated for 10 min. A 100 μ L aliquot of this solution was added to 50 mg of SCX resin in a small vial containing a magnetic stir bar and the slurry was
5 vortexed vigorously for 15 s. The vial was placed on top of a stir plate and the resin/sol-gel slurry was stirred continuously while one end of the individual 5 cm lengths of fused silica tubing (7) was dipped briefly (< 1 s) into it. After dipping, the tubing was supported vertically, with the dipped end at the bottom, and allowed to rest for 24 h at 20-22°C. The tubing was then placed into a 90°C oven for 4 hr.
10 These latter two processes resulted in polymerization of the sol-gel solution and solidification of the resin/sol-gel mixture into an embedded frit at the end of the fused silica column (8). The tubing was then flushed with water (approximately 50 μ L) in the direction from the embedded frit end to the open end of the tubing by use of a water-filled syringe and a fused silica tubing/syringe adapter. Residual water
15 was purged from the tubing by forcing air through the tubing in the same direction as described above. The frit-embedded tubing was dried at 90°C for 10 min. This furnished the completed column, which was then packed with SCX resin as described below (Section 3).

20 3. *Reactor packing*

For each column to be packed, a mark was placed on the fused silica tubing 2 cm from the end housed within the microfilter union (for columns prepared as described in section 2.1) or that contained the embedded frit (for columns prepared as described in section 2.2). A fused silica tubing/syringe adapter was fitted onto the
25 open end of the column. A slurry of pre-conditioned SCX resin in water (approximately 10 mg/mL) was prepared and drawn into a syringe. The syringe was fastened to the adapter and the slurry introduced into the column by depressing the syringe plunger with constant pressure. As the syringe plunger was depressed, the column was observed closely to monitor the progression of resin packing, which was
30 readily visible through the fused silica tubing. When the height of the packed resin (9; Figure 1, 2) reached the 2 cm mark on the tubing, the pressure on the syringe

plunger was stopped. The column was disassembled from the adapter, furnishing the completed SCX resin-packed column.

4. Flow inlet and flow outlet connections (Refer to Figures 1, 2).

5 The preparation of the flow inlet of the reactor was the same using either column format described in sections 2.1 and 2.2. The flow inlet of the reactor was prepared by inserting the open (top) end of the column tubing into a 1.5 cm length of capillary sleeve (10), such that the ends of the tubing and the sleeve were flush. The sleeve-covered end of the tubing was inserted into a fingertight fitting (11), such that the
10 end of the flush sleeve-covered tubing protruded through the fingertight fitting by approximately 1 mm. The fingertight fitting was then screwed into one opening (12) of a ZDV union (13). The other opening of the ZDV union (14) served to receive the fingertight fitting (15) that housed the fused silica tubing forming the flow outlet (16) of the pressure vessel solvent delivery system (section 5).

15 For reactor devices constructed using columns prepared using fused silica tubing fittings (section 2.1), the flow outlet of the reactor device was prepared with additional components. One end of a 4 cm length of fused silica tubing (17; 200 μ m inner diameter by 360 μ m outer diameter) was inserted into a capillary sleeve (18;
20 1.5 cm in length) such that the ends of the tubing and the sleeve were flush. The sleeve-covered end of the tubing was inserted into a fingertight fitting (19) such that the end of the flush sleeve-covered tubing protruded through the fingertight fitting by approximately 1 mm. The fingertight fitting was then screwed into the fingertight fitting opening (20) of the microfilter union (6) that housed the column.
25 In this format, the open end of the 4 cm length of tubing formed the flow outlet (21).

For reactor devices constructed using columns prepared with embedded SCX resin/sol-gel frits, no additional components were required to form the flow outlet of the reactor device. The flow outlet of the reactor was itself the frit embedded end of
30 the packed column (21).

B. Apparatus and General Operation

For delivery to the reactor, a vial containing the sample or buffer was placed in the cavity (8b) in the lower block of the pressure vessel solvent delivery system. The latter was connected to a high-pressure gas cylinder, controlled by a low-pressure regulator. A valve (7) placed in-line between the gas cylinder and the pressure vessel allowed for simple pressure-on/off operation. A bleed valve (6b) on a split line was incorporated to allow for de-pressurization of the pressure vessel when needed (See Figure 3).

10

In one embodiment, the pressure vessel is capable of housing a single vial. In another embodiment, the pressure vessel is capable of housing multiple vials and thus able to run multiple samples simultaneously (see Figure 4). In another embodiment, the pressure vessel is capable of housing multiple vials with the ability to individually control pressure applied to each sample. More detailed operating instructions are been described above (see Figure 5).

15

To change the solution being delivered to the device, the pressure vessel first must be de-pressurized. This was achieved by halting the pressure using the on/off valve, and bleeding the high-pressure gas from within the pressure vessel using the bleed valve. Once de-pressurized, the cavity within the pressure vessel became accessible and the vial containing the subsequent solution to be delivered could be substituted.

20

Two primary methods of solution delivery to the device were used in the methods described herein. In a first method, solutions were applied to the device continuously, to the point of depletion, if necessary. If the solution was depleted, the pressure vessel delivered a stream of gas to the device, effectively de-solvating the SCX resin to dryness. Most transitions between different solutions occurred with the device in this dehydrated state. Second, solutions were "infused" into the device by immediately halting delivery once the SCX resin was completely saturated in the solution and the solution just begins to emerge from the flow outlet. The

25

30

device was incubated in this saturated state to allow for chemical and/or enzymatic reactions to proceed. The infusion process typically consumed less than 2 μL of solution.

- 5 In a second method, solution delivery could be achieved by connecting the device in-line to a High Performance Liquid Chromatography (HPLC) or Fast Performance Liquid Chromatography (FPLC) pump. The required solutions could be manually injected through an injector port, or automatically injected with an autosampler. Alternatively, solution delivery could be achieved using a syringe connected to the
10 device.

C. Detailed Method of Operation

Buffers and Reagents

15

All buffers where indicated were filtered through a 0.2 μm syringe filter prior to use to prevent any particulate contaminants from entering the Reactor. All buffers containing trypsin were prepared immediately prior to use. All solutions containing NH_4HCO_3 were freshly prepared.

20

The following buffers and reagents were prepared as required:

	X:	50 mM H_3PO_4 (filtered)
	W:	MilliQ- H_2O (filtered)
25	W18:	H_2^{18}O
	K1:	10 mM KH_2PO_4 pH 3.0 (filtered)
	K2:	10 mM H_3PO_4 , prepared using W18 (filtered)
	A1:	1 M NH_4HCO_3
	A2:	100 mM NH_4HCO_3
30	A3:	1 M NH_4HCO_3 , prepared using W18
	A4:	100 mM NH_4HCO_3 , prepared using W18
	T1:	200 mM Tris-HCl, pH 8.0
	T2:	200 mM Tris-HCl, pH 8.0, prepared using W18

- R1: 1 M dithiothreitol (DTT)
 R2: 0.5 μ L R1 + 0.5 μ L A2 + 4 μ L W
 (100 mM DTT, 10 mM NH_4HCO_3)
 R3: 1 M DTT, prepared using W18
 5 R4: 0.5 μ L R3 + 0.5 μ L A4 + 4 μ L W18
 (100 mM DTT, 10 mM NH_4HCO_3 in H_2^{18}O)
 C1: 100 mM iodoacetamide
 C2: 100 mM iodoacetamide, prepared using W18
 D1: 1.25 μ L TS + 0.5 μ L A1 + 3.25 μ L W
 10 (0.5 mg/mL trypsin, 100 mM NH_4HCO_3)
 D2: 2.5 μ L T1 + 2.5 μ L W
 (100 mM Tris-HCl pH 8.0)
 D3: 1.25 μ L TS + 0.5 μ L A1 + 0.5 μ L C1 + 2.75 μ L W
 (0.5 mg/mL trypsin, 100 mM NH_4HCO_3 , 10 mM iodoacetamide)
 15 D4: 2.5 μ L T1 + 0.5 μ L C1 + 2 μ L W
 (100 mM Tris-HCl pH 8.0, 10 mM iodoacetamide)
 D5: 1.25 μ L TS18 + 0.5 μ L A3 + 0.5 μ L C2 + 2.75 μ L W18
 (0.5 mg/mL trypsin, 100 mM NH_4HCO_3 , 10 mM iodoacetamide
 in H_2^{18}O)
 20 D6: 2.5 μ L T2 + 0.5 μ L C2 + 2 μ L W18
 (100 mM Tris-HCl pH 8.0, 10 mM iodoacetamide in H_2^{18}O)
 TS: 2 mg/mL trypsin
 TS18: 2 mg/mL trypsin, prepared using W18

25 Procedure

The methods outlined below encompass several functions of the apparatus, including enzymatic digestion, chemical modification and isotopic labeling of polypeptides. The Basic procedure describes the enzymatic digestion of polypeptides by trypsin. As illustrated in the *Alternate* steps, the basic protocol can be amended to
 30 accommodate additional and/or modified reactions to enable chemical modification or labeling, for example. These examples showcase the flexibility of the

methodology, and in no way define the entire scope of potential applications. *Alternate A* describes a method that uses a different digestion buffer and second method of introducing enzyme to the sample. *Alternate B* augments the basic digestion protocol with the reduction of disulfide bonds between cysteine residues and subsequent alkylation of the free sulfhydryls. *Alternate C* details the isotopic labeling of tryptic peptides at their C-termini with ^{18}O . The *Alternate* methods can be used concurrently with the basic protocol to achieve the desired functionality.

Basic Protocol (Enzymatic Digestion of Protein Substrates)

1. **Device Equilibration.** Devices were equilibrated briefly with K1 prior to loading samples.
2. **Sample Preparation.** Protein samples were acidified by diluting with X. Samples were then centrifuged for 10 minutes at 4°C at $20800 \times g$ to pellet any insoluble material. The supernatants were transferred to fresh vials and placed in the pressure vessel for delivery to the device.
3. **Sample Loading.** Samples were loaded onto the device. Solution exiting the device flow outlet was collected for further analysis to determine the extent of unbound protein. Sample was loaded to the point of depletion and the SCX resin was rendered dry.
4. **First Wash.** Residual contaminants were washed from the device using $30 \mu\text{L}$ of K1.
5. **Second Wash.** The device was washed with $15 \mu\text{L}$ of W1.
6. **Enzymatic Digestion.** To enzymatically digest immobilized proteins, the device was infused with D1.

7. **Device Incubation.** To allow enzymatic digestion to occur, the device hydrated in D1 was incubated at room temperature for 1 hour.

8. **Elution.** Products were eluted from the device using 12 – 20 μL of A2 and collected in a vial.

9. **Storage.** Products were stored at -80°C .

Alternate A: Enzymatic Digestion of Protein Substrates

An alternative method for enzymatic digestion changes the point at which enzyme is introduced. With reference to the basic protocol described above, instead of applying trypsin to the proteins immobilized to the device, trypsin could be introduced concomitant with the sample during the sample loading step. Trypsin activity is inhibited under these conditions due to the acidic nature of X. Likewise, any proteinaceous enzyme could be applied to the device simultaneously with its targeted substrate, since conditions favoring substrate immobilization to the device should also promote enzyme immobilization. Referring to the Basic protocol again, the point where trypsin is usually introduced can be replaced with simply the introduction of buffer conditions that would allow trypsin activity to ensue.

1. **Device Equilibration.** Devices were equilibrated briefly with K1 prior to loading samples.

2. **Sample Preparation.** Protein samples were acidified by diluting with X. Samples were then centrifuged for 10 minutes at 4°C at $20800 \times g$ to pellet any insoluble material. The supernatants were transferred to fresh vials. To each sample, $0.5 \mu\text{L}$ of TS was added. Samples were placed in the pressure vessel for delivery to the Reactor.

3. **Sample Loading.** Samples were loaded onto the device. Solution exiting the device flow outlet was collected for further analysis to determine the extent of unbound protein. Sample was loaded to the point of depletion and the SCX resin was rendered dry.

5

4. **First Wash.** Residual contaminants were washed from the device using 30 μ L of K1.

5. **Second Wash.** The device was washed with 15 μ L of W1.

10

6. **Enzymatic Digestion.** To enzymatically digest immobilized proteins, the device was infused with D2, thereby activating trypsin through the favourable pH of the buffer.

15

7. **Device Incubation.** To allow the enzymatic digestion to occur, the device hydrated in D2 was incubated at room temperature for 1 hour.

8. **Elution.** Products were eluted from the device using 12 – 20 μ L of A2 and collected in a vial.

20

9. **Storage.** Products were stored at -80°C .

Alternate B: Serial Chemical and Enzymatic Transformation of Protein Substrates

25

1. **Equilibration.** Devices were equilibrated briefly with K1 prior to loading samples.

2. **Sample Preparation.** Protein samples were acidified by diluting with X. Samples were then centrifuged for 10 minutes at 4°C at $20800 \times g$ to pellet any insoluble material. The supernatants were transferred to fresh vials and placed in the pressure vessel for delivery to the Reactor.

30

3. **Sample Loading.** Samples were loaded onto the device. Solution exiting the device flow outlet was collected for further analysis to determine the extent of unbound protein. Sample was loaded to the point of depletion and the SCX resin was rendered dry.
5. 4. **First Wash.** Residual contaminants were washed from the device using 30 μ L of K1.
5. 5. **Second Wash.** The device was washed with 15 μ L of W1.
- 10 6. **Chemical Transformation.** To convert disulfide-bonded cysteine residues into their sulfhydryl form, the reducing agent, DTT, was applied to the immobilized proteins by infusing R2 into the device.
- 15 7. **Device Incubation.** The device, hydrated in R2, was incubated at room temperature for 30 minutes.
- 20 8. **Third Wash.** After the incubation period, R2 was expelled from the device and the SCX resin was rendered dry. The device was then washed with 2 μ L of K1 to remove residual R2.
- 25 9. **Enzymatic and Chemical Transformation.** To prevent disulfide bonds from reforming, the sulfhydryl groups of cysteine residues were covalently modified by reaction with iodoacetamide. Simultaneously, proteins were enzymatically digested with trypsin. This was accomplished by infusing the device with D3. To combine *Alternate A* and *Alternate B*, the device should be infused with D4.
- 30 10. **Device Incubation.** To allow the enzymatic and chemical transformations to occur, the device hydrated with the buffer in step 9 was incubated at room temperature for 1 hour.

11. **Elution.** Products were eluted from the device using 12 – 20 μ L of A2 and collected in a vial.

12. **Storage.** Products were stored at -80°C.

5

Alternate C: Serial Chemical and Enzymatic Transformation with Isotopic Labeling of Products

1. **Equilibration.** Devices were equilibrated briefly with K1 prior to loading samples.

10

2. **Sample Preparation.** Protein samples were acidified by diluting with X. Samples were then centrifuged for 10 minutes at 4°C at 20800 x g to pellet any insoluble material. The supernatants were transferred to fresh vials and placed in the pressure vessel for delivery to the Reactor.

15

3. **Sample Loading.** Samples were loaded onto the device. Solution exiting the device flow outlet was collected for further analysis to determine the extent of unbound protein. Sample was loaded to the point of depletion and the SCX resin was rendered dry.

20

4. **First Wash.** Residual contaminants were washed from the device using 30 μ L of K1.

25 5. **Second Wash.** The device was washed with 15 μ L of W18.

6. **Chemical Transformation.** To convert disulfide-bonded cysteine residues into their sulfhydryl form, the reducing agent, DTT, was applied to the immobilized proteins by infusing R4 into the device.

30

7. **Reactor Incubation.** The device, hydrated in R4, was incubated at room temperature for 30 minutes.

8. **Third Wash.** After the incubation period, R4 was expelled from the device and the device was run dry. The device was then washed with 2 μ L of K2 to remove residual R4.
- 5
9. **Enzymatic and Chemical Transformation.** To prevent disulfide bonds from reforming, the sulfhydryl groups of cysteine residues were covalently modified by reaction with iodoacetamide. Simultaneously, proteins were enzymatically digested with trypsin and the products isotopically labeled at their C-termini with ^{18}O . This was accomplished by infusing the device with D5. To combine *Alternate A* and *Alternate C*, the device should be infused with D6.
- 10
10. **Device Incubation.** To allow the enzymatic and chemical transformations to occur, the device hydrated with the buffer from step 9 was incubated at room temperature for 1 hour.
- 15
11. **Elution.** Products were eluted from the device using 12 – 20 μ L of A4 and collected in a vial.
- 20
12. **Storage.** Products were stored at -80°C .

Example 1 - Tryptic digestion of standard proteins using the Reactor

A mixture of four commercially available proteins (rabbit glycogen phosphorylase B, bovine serum albumin, bovine carbonic anhydrase, and horse heart myoglobin) was prepared in 50 mM phosphoric acid. Each protein was prepared to give a final concentration of 1 pmol/ μ L in the mixture. 10 μ L of this mixture (10 pmol each protein) was applied to an SCX column, washed, and digested according to the instructions outlined in the Basic Protocol of section C, above. The resulting elution fraction (~ 15 μ L) was diluted 5-fold and 2 μ L of the diluted fraction was analyzed on a LC-QSTAR mass spectrometer. Assuming complete digestion and recovery of peptides, this amounted to 267 fmol of each digested protein analyzed by LC/MS.

25

30

Figure 6 illustrates that the entire protein sample applied to the column was immobilized onto the SCX resin. If immobilization did not occur or if proteins were displaced from the SCX resin during the subsequent wash steps, proteins would elute in the various wash fractions and would be detected on the gel.

The resulting MS data were queried against protein databases and each of the 4 proteins was unambiguously identified. Using the Mascot searching algorithm (Matrix Science), the entire NCBI database was searched, producing the following results (top 20 hits shown):

gi 6093713	GLYCOGEN PHOSPHORYLASE, MUSCLE FORM (MYOPHOSPHORYLASE)
gi 223003	phosphorylase b, glycogen [<i>Oryctolagus cuniculus</i>]
gi 14916625	GLYCOGEN PHOSPHORYLASE, MUSCLE FORM (MYOPHOSPHORYLASE)
gi 225897	glycogen phosphorylase [<i>Homo sapiens</i>]
gi 2190337	(X58989) serum albumin [<i>Bos taurus</i>]
gi 2506462	MYOGLOBIN
gi 115453	CARBONIC ANHYDRASE II (CARBONATE DEHYDRATASE II) (CA-II)
gi 164318	(M36787) albumin [<i>Sus scrofa</i>]
gi 115460	CARBONIC ANHYDRASE II (CARBONATE DEHYDRATASE II) (CA-II)
gi 13124699	SERUM ALBUMIN PRECURSOR (ALLERGEN CAN F 3)
gi 1351908	SERUM ALBUMIN PRECURSOR (ALLERGEN FEL D 2)
gi 127691	MYOGLOBIN
gi 127641	MYOGLOBIN
gi 4506351	phosphorylase, glycogen; brain [<i>Homo sapiens</i>]
gi 87573	glycogen phosphorylase (EC 2.4.1.1) - human (fragment)
gi 127685	MYOGLOBIN
gi 127634	MYOGLOBIN
gi 70559	myoglobin - Indian elephant
gi 11935049	(AF304164) keratin 1 [<i>Homo sapiens</i>]
gi 127664	MYOGLOBIN

The Mascot search algorithm also lists the unique peptides found for each protein. Some peptides are listed more than once, corresponding to the fragmentation of the same peptide at different charge states (+2 or +3). This further reinforces the certainty of the presence of the particular peptide.

Number of Peptides Identified:

Phosphorylase B – 26 peptides

BSA – 13 peptides

Myoglobin – 10 peptides

Carbonic anhydrase – 10 peptides

Representative MS and MS/MS spectra acquired for this analysis are presented in Figures 7 and 8.

Collectively, these results demonstrate that the standard proteins were concentrated and immobilized onto the SCX resin and were digested very efficiently by trypsin using the reactor methodology. The resulting peptides were isolated and analyzed by MS without further purification, and database searching of the MS derived data unequivocally correctly identified each of the 4 proteins.

Example 2 - Tryptic digestion of Immunopurified Human Proteins using the Reactor

Standard protocols were employed to immunopurify an epitope-tagged protein (bait) from cultured human cells (hEK293 cells) and proteins that complex or interact with the bait protein. Briefly, human cells were transfected with DNA encoding the bait protein. Cells were cultured for 2 days and then were harvested and lysed using detergent-containing buffer. The clarified lysate was subjected to immunopurification using an immobilized antibody resin against the specific epitope. The resin was collected, and the immunopurified bait and associated proteins were eluted from the antibody resin using 50 mM phosphoric acid. A portion of the eluent (containing ~ 5 µg total protein) was analyzed by SDS-PAGE (see Figure 9) to characterize the immunopurified complex and to ensure that the immunopurification process was successful. Another portion of the eluent (~ 500 ng total protein, or ~ 10 pmol total protein) was subjected to trypsin digestion using the

method of Alternate B, above. The elution fraction collected from the device following digestion was analyzed using an LCQ-DECA mass spectrometer.

The bait protein exemplified in this case, human SKB1, has been previously shown to interact with several specific associating proteins. Each of these associating proteins, a list of which is shown in Figure 9, was identified using this method.

These results exemplify the utility and advantages of the reactor based methodology. The protein sample in this case was isolated from human cells. While the immunopurification process does purify the protein complex, the sample is nonetheless contaminated with other cellular components and reagents used during the process. In particular, residual detergent from the lysis procedure is extremely problematic to MS analysis. The reactor-based method circumvents these problems. The amount of protein sample required for the reactor methodology is appreciably less than that required for standard gel-based methods (the data from the reactor-based experiment was obtained using approximately 10% of the amount of material needed for the gel-based experiment). Furthermore, in the case of the latter, each protein band from the gel (e.g. Figure 9) must be excised, digested and analyzed separately and only those bands visible on the gel would be processed. The reactor-based method streamlines the entire process into a single, integrated system.

Example 3 - Reduction and alkylation of sulfhydryl groups of peptides

Table 1

Peptide	Sequence	Reduced MW	Disulfide-bonded MW	Singly-Alkylated MW	Doubly-Alkylated MW
1	CYFQNCPK	1001.41	999.39	1058.47	1115.53
2	CYFQNCPR	1029.42	1027.40	1086.48	1143.54
3	CDPGYIGSR	966.42	1931.84	1023.48	-

A mixture of 3 cysteine-containing peptides in their disulfide-bonded (oxidized) state, listed in Table 1, above, was prepared in 50mM H₃PO₄, and 50 pmol total peptide was loaded onto a device. The immobilized peptides were then processed according to the instructions in Section C, Alternate B, above.

Shown in Figure 10 is the MALDI-Tof mass spectrum of the peptide mixture following chemical reduction and alkylation using the reactor based method. Comparing relative peak intensities, it can be seen that, for each peptide, more than 80% are fully alkylated, as illustrated graphically. These results clearly demonstrate the feasibility of chemical transformation of immobilized polypeptides.

Example 4 - Serial Transformation: Reduction, Alkylation and Tryptic Digestion of Proteins.

A mixture of 4 commercially available proteins (rabbit glycogen phosphorylase B, bovine serum albumin, chicken ovalbumin, horse heart myoglobin) was prepared in 50 mM phosphoric acid, each at a concentration of 2 pmol/ μ L. 10 μ L of this mixture (20 pmol of each protein) was loaded onto a reactor. The immobilized proteins were then processed according to the instructions in Section C, Alternate B, above.

A parallel sample, which served as a control, was processed according to the instructions outlined in Section C, Basic Protocol, above. Thus, the first sample was subjected to chemical reduction, alkylation by iodoacetamide and enzymatic digestion with trypsin. In contrast, the control sample was simply digested with trypsin.

Bovine Serum Albumin (BSA) contains 17 disulfide bonds making it an ideal substrate for this experiment. The MALDI-Tof peptide mass fingerprints from both the control and experimental samples were searched using Mascot and the identified BSA peptides were compared for the presence of iodoacetamide-modified cysteine residues. The representative spectra shown in Figure 11 illustrate the modification of cysteine residues for three tryptic peptides from BSA.

Other cysteine-containing BSA tryptic peptides that were alkylated and identified in the experimental sample, but *not* in the control sample included :

MPCTEDYLSLILNR + 1 IA
 YNGVFQECCQAEDK + 2 IA
 NECFLSHKDDSPDLPK + 1 IA
 CCAADDKEACFAVEGPK + 3 IA
 5 ECCHGDLLECADDRADLAK + 3 IA
 CCTKPESERMPCTEDYLSLILNR + 1 IA
 TCVADESHAGCEKSLHTLFGDELCK + 2 IA

Similarly, cysteine-containing tryptic peptides from Phosphorylase B and
 10 Ovalbumin were identified as being modified by iodoacetamide. These results
 clearly demonstrate that both chemical and enzymatic transformation of proteins are
 efficiently achieved using the reactor-based methodology.

Example 5 - Protein Quantitation using Stable Isotope Labeling with H_2^{18}O

15 Two separate samples (A and B), each containing the same eight commercially
 available proteins but at different absolute amounts, were prepared in 50 mM H_3PO_4
 (100 μL total volume) as outlined in Table 2, below. In Sample A, the proteins
 ranged in absolute amounts from 100 fmol (Cytochrome C) to 40 pmol
 20 (Myoglobin). In the case of Sample B, the proteins ranged in absolute amounts from
 200 fmol (Carbonic Anhydrase) to 30 pmol (Ovalbumin). The ratio of the
 individual proteins present in Sample A to Sample B varied from 0.05 (or 1:20,
 Aldolase) to 10 (or 10:1, Myoglobin). The total protein content in both samples was
 approximately 3.6 μg . Thus, the two samples represent complex mixtures of
 25 proteins present in a broad range of absolute amounts and, therefore, were
 representative of complex mixtures that would be obtained from real biological
 samples. Furthermore, the total protein content of each sample was also
 representative of the amount of protein material that would realistically be isolated
 from a biological sample. Therefore, as designed, Sample A and Sample B
 30 represented a worthy model system for interrogation by the practice of stable isotope
 labeling using ^{18}O -labeled water (H_2^{18}O) for quantitative proteomics analysis.

Table 2.

Protein	Absolute Amount of Protein in Each Sample (pmol)		Theoretical Protein Ratio A:B	Experimental Protein Ratio Determined By MS Analysis A:B
	Sample A	Sample B		
Aldolase	0.2	4	0.05	0.08
Albumin	2	20	0.1	0.15
Carbonic Anhydrase	0.5	0.2	2.5	1.63
Cytochrome C	0.1	0.3	0.33	0.44
Enolase	10	10	1	0.95
Myoglobin	40	4	10	8.70
Ovalbumin	30	30	1	0.89
Phosphorylase B	10	2	5	6.00

Sample A and Sample B were each separately subjected to sample processing with reactors fabricated using columns prepared with embedded SCX resin/sol-gel frits.

5

Sample A was selected for processing so that the peptides would be labeled at their carboxy terminus with ^{18}O . Thus, Sample A was applied to the device, washed, treated with DTT, digested with trypsin and alkylated with iodoacetamide according to the instructions outlined above (Method *Alternate C*; using D6 at step 9) using the appropriate H_2^{18}O -enriched buffer reagents. The resulting elution fraction (18 μL) was collected and 1.5 μL of 50% formic acid (in H_2^{18}O) was added generating the Sample A analyte.

10

Sample B was selected for standard sample processing. Thus, Sample B was applied to a second device, washed, treated with DTT, digested with trypsin and alkylated with iodoacetamide according to the instructions outlined above (Method *Alternate B*; using D4 at step 9) using the appropriate buffer reagents that were prepared in natural abundance water (H_2^{16}O). The resulting elution fraction (18 μL) was collected and 1.5 μL of 50% formic acid (in H_2^{16}O) was added generating the Sample B analyte.

15
20

A portion of the Sample A analyte (2 μL) was analyzed without further purification by LC/MS/MS using an Agilent 1100 HPLC coupled to an AB/Sciex QStar mass

spectrometer. The resulting MS data were queried against a database containing the sequences of the eight proteins using the Mascot searching algorithm. The searching parameters were set to include a variable modification for ^{18}O labeling of the carboxy terminus of the peptide. The search result report generated indicated that the proteins were correctly identified. The Mascot result report also listed the unique peptides identified for each protein, which indicated that the greater majority of peptides identified by MS sequencing, were labeled at their carboxy terminus with ^{18}O .

- 10 In a separate experiment, equal portions of the Sample A analyte and the Sample B analyte were mixed, and 2.5 μL of the resultant 1:1 mixture was analyzed by LC/MS/MS without further purification using an Agilent 1100 HPLC coupled to an AB/Sciex QStar mass spectrometer. The resulting MS data were queried against a database containing the sequences of the eight proteins using the Mascot searching algorithm. The searching parameters were set to include a variable modification for ^{18}O labeling of the carboxy terminus of the peptide. The search result report generated indicated that the proteins were correctly identified.

For the experiment described above for the 1:1 mixture, tryptic peptides generated from Sample A are labeled at their carboxy terminus with the heavy version of oxygen (*i.e.* ^{18}O) and tryptic peptides generated from Sample B are labeled at their carboxy terminus with the light version of oxygen (*i.e.* ^{16}O). Thus, when mixed, the heavy- and light-labeled version of peptides will form an analyte pair of identical peptide sequence and chemical composition but of different mass, which will appear as separate mass peaks in a mass spectrum. Using known practices in the art [Stewart, I.I., Thomson, T. and Figeys, D. (2001) *Rapid Commun. Mass Spectrom.*, 15, 2456-2465; Reynolds, K. J., Yao, X., and Fenselau, C. (2001) *J. Proteome Res.* 1, 27-33] the mass peaks are deconvoluted and an intensity assigned to the heavy and light mass peaks. The ratio between these intensities is equal to the ratio between the amount of light and heavy version of the peptide. By extension, this provides a ratio of the absolute amount of a given protein in Sample A to the absolute amount of the same protein in Sample B.

Several peptides that were identified above for each protein were selected for additional analysis. The mass spectrum for a given peptide-pair was retrieved, and intensities were assigned to the heavy and light versions using the practice described above. In each case, the intensity of the heavy-peptide from Sample A was divided by the intensity of the light-peptide from sample B. For each of the eight proteins, this provided an experimentally derived ratio for the absolute amount of the protein in Sample A to Sample B (Table 2). The experimentally derived ratios are in strong agreement with the theoretical protein ratio (Table 2).

10

These results demonstrate that sample processing using the reactor-based device and the procedures described herein provide accurate results on the relative amount of a given protein present in two samples. Therefore, the reactor-based device and procedures provide a reliable method to perform quantitative proteomics analysis.

15

Furthermore, these results demonstrate that the standard proteins were concentrated and immobilized onto the SCX resin, and were digested very efficiently by trypsin using the reactor methodology, even though there existed a difference in the complexity of the proteins in Sample A and Sample B.

20

In the case of Sample A, which was processed for purposes of ^{18}O -labeling, the results indicate that a protein sample present in a medium containing only H_2^{16}O can be transferred into a medium containing highly enriched H_2^{18}O . Furthermore, this is accomplished without the need for drying down the sample and reconstituting it in highly enriched H_2^{18}O or significantly diluting the sample into highly enriched H_2^{18}O . If the efficient transfer did not occur, then the greater majority of peptides identified by MS sequencing would not have been labeled at their carboxy terminus with ^{18}O .

25

Lastly, the results demonstrate that the efficient labeling of peptides with ^{18}O can be achieved while using only minimal amounts of highly enriched H_2^{18}O . By application of the method, less than 35 μL of H_2^{18}O is consumed in the course of

30

sample processing using the reactor device. Therefore, the method represents a very cost effective method for stable isotope labeling with ^{18}O , and by extension, a cost effective method for performing quantitative proteomics analysis.

- 5 It will be appreciated that the methods and apparatus of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are described herein. It will be apparent to those skilled in the art that other embodiments exist that do not depart from the spirit of the invention.
- 10 Further, whilst the examples disclosed herein use nanogram quantities of proteins, the reactor, device and apparatus may also be used on a larger scale to handle milligram or even gram quantities of material. Any modifications required to facilitate such scale-up (for example, to the solvent delivery system) will be apparent to those skilled in the art.

Claims

1. A method for processing protein or peptide samples, comprising:
 - (i) reversibly immobilizing said peptide or protein samples onto a solid support;
 - 5 (ii) transforming the immobilized peptide or protein by solid-phase chemical or enzymatic means, or a combination thereof;
 - (iii) eluting the resulting peptide- or protein-derived fragments from said solid support; and
 - (iv) recovering the fragments.
- 10 2. The method of claim 1, wherein the solid support is an ion-exchange resin.
3. The method of claim 2, wherein the resin is a cation exchange resin.
4. The method of claim 1, wherein the transformation is digestion of the peptide or protein.
5. The method of claim 4, wherein the digestion is carried out using an enzyme.
- 15 6. The method of claim 5, wherein the enzyme is trypsin.
7. The method of claim 2, where the immobilization and elution are pH-dependent.
8. The method of claim 2, where the immobilization and elution are ionic strength-dependent.
- 20 9. The method of claim 1, wherein the transformation is chemical transformation of the peptide or protein.
10. The method of claim 9, wherein the transformation is reduction of the peptide or protein.
11. The method of claim 9, wherein the transformation is alkylation of the
25 peptide or protein.

12. The method of claim 11, wherein the transformation is alkylation of cysteine residues.
13. The method of claim 1, wherein the processing is carried out in semi-batch mode.
- 5 14. A method for the processing of peptide or protein samples according to the method of claim 1, wherein the total peptide or protein amount is less than about 1 pmol.
- 15 15. A method for the processing of peptide or protein samples according to the method of claim 14, wherein the total peptide or protein amount is less than about 100 fmol.
- 16 16. A method for the processing of peptide or protein samples according to the method of claim 15, wherein the total peptide or protein amount is less than about 10 fmol.
- 15 17. A method for the processing of peptide or protein samples according to the method of claim 16, wherein the total peptide or protein amount is less than about 1 fmol.
18. The method of claim 1, wherein said fragments are suitable for use in mass spectrometer analysis.
- 20 19. The method of claim 1, further comprising washing said samples after step (i) with one or more buffers before step (ii).
20. The method of claim 1, further comprising dehydrating said protein or peptide samples on said solid support by purging all solvents used to dissolve said samples after step (i), followed by rehydrating said protein or peptide samples before step (ii).
- 25 21. The method of claim 20, wherein said dehydrating and rehydrating steps are separated by a period of storage time.

22. The method of claim 1, wherein said solid support is ion-exchange resin packed in a column.
23. The method of claim 22, wherein said resin is strong cation exchange resin.
24. The method of claim 1, wherein said protein or peptide is immunoprecipitated from a biological sample.
25. The method of claim 24, wherein said biological sample is a lysate of a cell expressing said protein or peptide.
26. The method of claim 1, wherein at least one of steps (i), (iii), or (iv) is facilitated by a solvent delivery system.
27. The method of claim 26, wherein said solvent delivery system is capable of delivering solvents to more than one independently operating solid supports.
28. A method of determining the ratio of proteins in a first and a second samples, the method comprising:
- (a) processing said first sample using the method of claim 5 in the presence of H_2^{18}O , thereby labeling the carboxy termini of the peptide fragments resulting from the digestion with ^{18}O ;
 - (b) processing said second sample using the method of claim 5 at the presence of H_2^{16}O , thereby labeling the carboxy termini of the peptide fragments resulting from the digestion with ^{16}O ;
 - (c) analyzing all peptide fragments of steps (a) and (b) using mass spectrometry by determining the ratio of each pair isotopically labeled fragment, thereby determining the ratio of proteins in said first and second sample.
29. An apparatus for processing protein or peptide samples according to claim 1, comprising:
- (i) a reactor comprising a solid support;
 - (ii) a solvent delivery system; and
 - (iii) a means for connecting (i) and (ii).




Figure 1.

2/11




Figure 2.

3/11




Figure 3.

SUBSTITUTE SHEET (RULE 26)




Figure 4.

5/11





Figure 5.

SUBSTITUTE SHEET (RULE 26)

6/11



- 1 – starting material (10 pmol each protein)
- 2 – column flow through (FT fraction)
- 3 – First wash fraction
- 4 – Second wash fraction

Figure 6.

Phosphorylase B peptide HLQIYEINQR
 Monoisotopic mass = 1425.77
 Observed mass (2+ charge) = 713.90

Phosphorylase B peptide TNFDAFPDK
Monoisotopic mass = 1053.48
Observed mass (2+ charge) = 527.70





Figure 7.

8/11

Carbonic anhydrase peptide VLDALDSIK

Monoisotopic mass = 972.55

Observed mass (2+ charge) = 487.30

**BSA peptide LVNELTEFAK**

Monoisotopic mass = 1162.62

Observed mass (2+ charge) = 582.30





Figure 8.

9/11



SKB1 Interacting
Proteins

GRF2
HSP70
α-tubulin
β-tubulin
MGC2722
p1Cln
Calmodulin
SMD1
SMD2
SME
SMG

Figure 9.

10/11





Figure 10.



(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 July 2003 (24.07.2003)

PCT

(10) International Publication Number
WO 2003/060524 A3

(51) International Patent Classification⁷: G01N 33/68, 27/64

(21) International Application Number:
PCT/CA2002/002024

(22) International Filing Date:
30 December 2002 (30.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/343,859 28 December 2001 (28.12.2001) US

(71) Applicant (for all designated States except US): MDS
PROTEOMICS INC. [CA/CA]; 251 Attwell Drive,
Toronto, Ontario M9W 7H4 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DUEWEL, Henry
[CA/CA]; 350 Queens Quay West, Apt. 1310, Toronto,
Ontario M5V 3A7 (CA). GOH, Theo [CA/CA]; 1055 Bay
Street, Apt. 1116, Toronto, Ontario M5S 3A3 (CA). LEBI-
HAN, Thierry [CA/CA]; #206-3310 Fieldgate Dr., Missis-
sauga, Ontario L4X 2J1 (CA).

(74) Agent: BERESKIN & PARR; 40 King Street West, 40th
Floor, Toronto, Ontario M5H 3Y2 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
11 March 2004

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ENZYME/CHEMICAL REACTOR BASED PROTEIN PROCESSING METHOD FOR PROTEOMICS ANALYSIS
BY MASS SPECTROMETRY

(57) Abstract: A method and tools for the biochemical processing of protein samples towards their analysis and identification by, for example, mass spectrometry (MS). The method involves the reversible (non-covalent) immobilization, purification and concentration of proteins onto a solid surface and subsequent solid-phase enzyme-catalyzed proteolysis of the proteins. The constituent peptides are recovered in near-quantitative yields in a format ideally suited for identification by routine MS technologies. The process is easily adapted such that additional chemical and/or enzymatic transformation(s) of the immobilized proteins or peptides can be performed to facilitate the acquisition of and increase the information content obtained from the MS analysis.

WO 2003/060524 A3

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 02/02024

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/68 G01N27/64

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE, PAJ, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/15655 A (RECIO ISIDRA ;VISSE SERVAAS (NL); NIZO FOOD RESEARCH (NL)) 23 March 2000 (2000-03-23)	1-10, 18, 19, 26, 27
Y	the whole document	11-17, 20-25, 28
X	DATABASE WPI 'Online! DERWENT PUBLICATIONS LTD., LONDON, GB; AZUMA H: "Edible protein hydrolyzate mfr- from animal protein using proteolytic enzyme" XP002128234 Database accession no. 1973-19518u abstract & JP 48 010543 B (AZUMA H) 4 April 1973 (1973-04-04) ----- -/--	1-5

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

3 September 2003

Date of mailing of the international search report

13.01.04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Thumb, W

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 322 970 B1 (LOUGH DAVID ET AL) 27 November 2001 (2001-11-27) cited in the application column 3 - column 6 column 33, line 43 - column 34, line 23 column 49 columns 55-56	1-12, 18, 19, 26, 27
Y	the whole document	13-17, 20-25, 28
X	----- QIAN XIAOHONG ET AL: "Direct analysis of the products of sequential cleavages of peptides and proteins affinity-bound to immobilized metal ion beads by matrix-assisted laser desorption/ionization mass spectrometry." ANALYTICAL BIOCHEMISTRY, vol. 274, no. 2, 15 October 1999 (1999-10-15), pages 174-180, XP002253232 ISSN: 0003-2697	1, 4-6, 18, 19, 24-27
Y	page 175, column 2 the whole document	2, 3, 7-17, 20-23, 28
X	----- ZHOU W ET AL: "Detection and sequencing of phosphopeptides affinity bound to immobilized metal ion beads by matrix-assisted laser desorption/ionization mass spectrometry" JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, ELSEVIER SCIENCE INC., NEW YORK, NY, US, vol. 11, no. 4, April 2000 (2000-04), pages 273-282, XP004191625 ISSN: 1044-0305	1, 4-6, 18, 19, 24-27
Y	page 275 the whole document	2, 3, 7-17, 20-23, 28
	----- -/-	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 02/02024

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WOODS AMINA S ET AL: "Simplified high-sensitivity sequencing of a major histocompatibility complex class I-associated immunoreactive peptide using matrix-assisted laser desorption/ionization mass spectrometry." ANALYTICAL BIOCHEMISTRY, vol. 226, no. 1, 1995, pages 15-25, XP002253233 ISSN: 0003-2697 abstract page 16, column 1, paragraph 1 page 17, column 1, paragraph 4 - page 18, column 1, paragraph 1</p>	1,4-6, 13-19, 24-27
Y	<p>SCHNOELZER MARTINA ET AL: "Protease-catalyzed incorporation of 180 into peptide fragments and its application for protein sequencing by electrospray and matrix-assisted laser desorption/ionization mass spectrometry." ELECTROPHORESIS, vol. 17, no. 5, 1996, pages 945-953, XP009016679 ISSN: 0173-0835 abstract</p>	28
Y	<p>KOSAKA T ET AL: "Identification and C-terminal characterization of proteins from two-dimensional polyacrylamide gels by a combination of isotopic labeling and nanoelectrospray Fourier transform ion cyclotron resonance mass spectrometry." ANALYTICAL CHEMISTRY. UNITED STATES 15 MAR 2000, vol. 72, no. 6, 15 March 2000 (2000-03-15), pages 1179-1185, XP002253247 ISSN: 0003-2700 the whole document</p>	28
A	<p>NUWAYSIR AND STULTS: "Electrospray ionisation mass spectrometry of phosphopeptides isolated by on-line immobilized metal-ion affinity chromatography" J AM SOC MASS SPECTROM, vol. 4, 1993, pages 662-669, XP009016554 abstract</p>	1-28

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 02/02024

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>YATES J R: "SPECIAL FEATURE: TUTORIAL MASS SPECTROMETRY AND THE AGE OF THE PROTEOME" JOURNAL OF MASS SPECTROMETRY, WILEY, CHICHESTER, GB, vol. 33, no. 1, 1998, pages 1-19,1, XP002908492 ISSN: 1076-5174 the whole document</p>	1-28
A	<p>ZHANG ZHONGLI ET AL: "Multiple separations facilitate identification of protein variants by mass spectrometry." PROTEOMICS, vol. 1, no. 8, August 2001 (2001-08), pages 1001-1009, XP002253248 ISSN: 1615-9853 the whole document</p>	1-28

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 02/02024

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see PCT/ISA/210 annex

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-28

A method for processing protein or peptide samples comprising the step of reversibly immobilising said protein or peptide samples onto a solid support and transforming said immobilised peptide or proteins by solid-phase chemical or enzymatic means.

2. claim: 29

An apparatus for performing methods including the presence of a solid phase and handling of solvent.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/CA 02/02024

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0015655	A	23-03-2000	AT 242782 T	15-06-2003
			AU 6194499 A	03-04-2000
			CA 2342395 A1	23-03-2000
			DE 69908790 D1	17-07-2003
			WO 0015655 A1	23-03-2000
			EP 1114060 A1	11-07-2001
			JP 2002532383 T	02-10-2002
			NZ 510539 A	30-06-2003
JP 48010543	B	04-04-1973	NONE	
US 6322970	B1	27-11-2001	US 6207370 B1	27-03-2001
			US 2003003465 A1	02-01-2003
			US 6387628 B1	14-05-2002
			AU 744266 B2	21-02-2002
			AU 9129898 A	22-03-1999
			CA 2300356 A1	11-03-1999
			DE 19882657 C2	13-03-2003
			DE 19882657 T0	24-08-2000
			EP 1296143 A2	26-03-2003
			EP 1010008 A2	21-06-2000
			JP 2001515209 T	18-09-2001
			NO 20001043 A	02-05-2000
			WO 9912040 A2	11-03-1999

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)